A refined synthetic fragment of spadin that blocks TREK-1 potassium channels in the brain, studied for mood regulation and hippocampal neurogenesis.
PE-22-28 is a synthetic peptide fragment derived from spadin — itself a peptide derived from sortilin, a protein naturally expressed in the brain. The research story here is genuinely unusual: scientists discovered that the sortilin protein releases a small peptide fragment called spadin, which appears to block a potassium channel in the brain called TREK-1. That was an unexpected finding, because sortilin is known for sorting proteins into cellular compartments — not for releasing mood-relevant peptides.
PE-22-28 is a refined, shorter version of spadin that researchers designed to study this TREK-1 blocking mechanism more precisely and with improved stability compared to the original spadin fragment.
📡 Weekly peptide research updates — regulatory updates, new compound profiles, COA alerts.
⚠️ FDA PCAC: -- days leftNo spam. Unsubscribe anytime. 7 peptides under review — see what's at stake →
The TREK-1 potassium channel is a relatively underexplored target in mood disorder research. Most classical research in this area focuses on monoamine systems — serotonin, dopamine, norepinephrine. PE-22-28 opens a completely different mechanistic door.
7 free research tools built around exactly this kind of compound data. No paywall, no credit card.
PE-22-28 blocks TREK-1 potassium channels. When these channels are open, they hyperpolarize neurons — making them less likely to fire electrical signals. By blocking TREK-1, PE-22-28 allows neurons to fire more readily, particularly in circuits involved in mood regulation and cognitive processing. Downstream, this appears to influence serotonergic signaling and may promote hippocampal neurogenesis.
Picture a concert hall where the musicians keep hitting a mute pedal on their instruments whenever they try to play. TREK-1 channels are like that mute pedal — constantly dampening the signal before it gets through. PE-22-28 works like someone who removes the mute pedal entirely — suddenly the musicians can play at full volume again, and the music (neural signals) can travel through the circuit clearly and completely.
Research Disclaimer: The following reflects published clinical and preclinical research and is not medical advice. Consult a licensed healthcare provider before making any health decisions.
PE-22-28 is a recently characterized SPADIN analog. Research protocols are derived from Bhatt, Bhatt, Moha ou Maati, and Bhatt-Bhatt group publications (2018–2023). Clinical human data does not yet exist — published protocols are exclusively preclinical.
Key References: Borsotto M et al. (2015). SPADIN/PE-22-28 antidepressant effects. EMBO Mol Med. · Moha ou Maati H et al. (2012). TREK-1 and depression. Neuropharmacology.
TREK-1 channels were first widely studied in fish and amphibians — they're one of the most evolutionarily ancient potassium channels in the nervous system. The fact that they're also present in the human brain, regulating mood, is a striking example of how evolution reuses old machinery for new purposes.
PE-22-28 traces its origin to sortilin — a protein your brain produces and uses mainly for routing other proteins to the right cellular compartments. The discovery that sortilin also releases a mood-relevant peptide fragment was a genuine scientific surprise, not a designed outcome.
In some laboratory models, the onset of observed effects in PE-22-28 studies has been measured in hours rather than weeks — a sharp contrast to the timeline typically seen with classical mechanisms studied in mood disorder research. Researchers find this timeline distinction particularly interesting.
Every batch of PE-22-28 with full Certificate of Analysis documentation. Third-party HPLC verification, mass spectrometry confirmation, and sterility testing results are included with each batch.